Q&A clinic on Substance, Organisation, Referentials Management Services - March 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, from 10 March 2026, 11:00 (CET) to 10 March 2026, 12:00 (CET)

Moventig

Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)

Guidance on the electronic submission of information on investigational medicinal products for human use in the Extended EudraVigilance medicinal product dictionary (XEVMPD)

Orphan designation: dibotatug Treatment of large granular lymphocytic leukaemia, 25/03/2026 Positive

Committee for Medicinal Products for Human Use (CHMP): 20-23 April 2026, European Medicines Agency, Amsterdam, the Netherlands, from 20 April 2026 to 23 April 2026

Annex to agenda of the CHMP meeting 20-23 April 2026

Agenda of the CHMP meeting 20-23 April 2026

Orphan designation: dusquetide Treatment of Behçet's Disease, 25/03/2026 Positive

Human medicines European public assessment report (EPAR): Roteas, edoxaban, Date of authorisation: 19/04/2017, Revision: 15, Status: Authorised